Author: Bastard, Paul; Michailidis, Eleftherios; Hoffmann, Hans-Heinrich; Chbihi, Marwa; Le Voyer, Tom; Rosain, Jérémie; Philippot, Quentin; Seeleuthner, Yoann; Gervais, Adrian; Materna, Marie; de Oliveira, Patricia Mouta Nunes; Maia, Maria de Lourdes S.; Dinis Ano Bom, Ana Paula; Azamor, Tamiris; Araújo da Conceição, Deborah; Goudouris, Ekaterini; Homma, Akira; Slesak, Günther; Schäfer, Johannes; Pulendran, Bali; Miller, Joseph D.; Huits, Ralph; Yang, Rui; Rosen, Lindsey B.; Bizien, Lucy; Lorenzo, Lazaro; Chrabieh, Maya; Erazo, Lucia V.; Rozenberg, Flore; Jeljeli, Mohamed Maxime; Béziat, Vivien; Holland, Steven M.; Cobat, Aurélie; Notarangelo, Luigi D.; Su, Helen C.; Ahmed, Rafi; Puel, Anne; Zhang, Shen-Ying; Abel, Laurent; Seligman, Stephen J.; Zhang, Qian; MacDonald, Margaret R.; Jouanguy, Emmanuelle; Rice, Charles M.; Casanova, Jean-Laurent
Title: Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine Cord-id: i4qotw0r Document date: 2021_2_5
ID: i4qotw0r
Snippet: Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at th
Document: Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date